cmAngio® vs Rhythm360

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by CureMetrix
VS
by RhythmScience

AI Verdict

Tool A, cmAngio®, focuses on identifying cardiovascular risk by detecting Breast Arterial Calcifications (BAC) on mammograms, primarily aiding in early risk assessment through imaging analysis. In contrast, Tool B, Rhythm360, is an integrated platform that unifies cardiac monitoring data from various devices to provide actionable insights for managing established conditions like hypertension, heart failure, and arrhythmias. While both contribute to cardiovascular health, they address different stages of care and utilize distinct data modalities and AI applications.

Choose cmAngio® if…

Choose cmAngio® if your clinic aims to proactively identify cardiovascular risk in women by leveraging existing mammography screenings. This tool is ideal for integrating AI-powered detection of Breast Arterial Calcifications (BAC) into routine breast imaging workflows, providing valuable insights for early risk assessment without additional procedures or radiation. It's particularly suited for practices looking to enhance women's health initiatives by connecting breast health with cardiovascular well-being.

View cmAngio® →

Choose Rhythm360 if…

Choose Rhythm360 if your cardiology practice requires a comprehensive, integrated platform to manage and interpret cardiac monitoring data from a diverse range of devices. This solution is best for clinics seeking to reduce alert fatigue, streamline workflows with AI-driven triage and automated billing, and optimize the management of patients with hypertension, heart failure, and arrhythmias through actionable, unified insights. It's especially beneficial for practices with a high volume of remote monitoring patients across multiple device manufacturers.

View Rhythm360 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature cmAngio® Rhythm360
Pricing Paid, out-of-pocket Flexible pricing model that scales with clinic size and platform usage.
Deployment Cloud-based, integrates with any DICOM-compliant viewer Cloud-based SaaS platform
BAA Available Unknown Yes AI-estimated
FDA Status Cleared AI-estimated Unknown
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Rhythm360

Tool B (Rhythm360) offers a HIPAA-compliant mobile application for clinicians and extensive bi-directional EHR integration with major systems, suggesting a highly integrated and accessible user experience. While Tool A (cmAngiou00ae) emphasizes quick installation and compatibility with DICOM viewers, Tool B's broader integration with clinical workflows and mobile access provides a more comprehensive usability profile for diverse clinical settings.

Clinical Value

Rhythm360

Tool B (Rhythm360) provides a comprehensive platform for managing multiple cardiac conditions, offering AI-driven alert triage for 80% faster response times, reducing alert fatigue, and including predictive algorithms for heart failure. While Tool A (cmAngiou00ae) offers significant value by detecting Breast Arterial Calcifications on mammograms for early cardiovascular risk assessment, Tool B's direct impact on active patient management, efficiency, and predictive capabilities across various cardiac issues offers a broader and more immediate clinical benefit.

Pricing & Value

Rhythm360

Tool B (Rhythm360) offers a flexible, SaaS-based pricing model that scales with clinic size and platform usage, and explicitly mentions automated CPT code documentation and billing, directly linking to revenue generation and operational efficiency. Tool A's (cmAngiou00ae) pricing is not publicly available, though it mentions potential no-cost implementation offers, making its overall value proposition less transparent and harder to quantify financially compared to Tool B's clear value-add features.

Enterprise Readiness

Rhythm360

Tool B (Rhythm360) demonstrates superior enterprise readiness with explicit mention of a Business Associate Agreement (BAA), extensive bi-directional EHR integrations with major vendors like Epic and Cerner, and vendor-neutral data aggregation from all major cardiac device OEMs. Tool A (cmAngiou00ae) requires contacting the vendor for BAA details and does not specify its EHR integration capabilities, making Tool B's interoperability and compliance posture more robust for large-scale deployments.

Innovation

cmAngio®

Tool A (cmAngiou00ae) presents a highly innovative approach by leveraging existing mammography data to detect Breast Arterial Calcifications, providing novel insights into cardiovascular health without additional radiation or procedures. While Tool B (Rhythm360) offers advanced AI for data aggregation, alert triage, and predictive algorithms, Tool A's ability to extract new, critical clinical value from routinely collected imaging data represents a more fundamental and unique application of AI in medical diagnostics.

Support & Docs

Rhythm360

Tool B (Rhythm360) explicitly offers 'Optional 24/7/365 oversight by certified cardiac technicians (CCTs),' indicating a robust and continuous support mechanism for its users. Tool A (cmAngiou00ae) does not provide any information regarding its support offerings or documentation in the provided specifications, making Tool B the clear winner in this dimension due to its transparent and comprehensive support model.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature cmAngio® Rhythm360
Product Name cmAngiou00ae Rhythm360
Company CureMetrix RhythmScience
Primary Use Case Detecting Breast Arterial Calcifications (BAC) on mammograms for cardiovascular health insights and early risk assessment. Unifying cardiac monitoring data from various devices, providing actionable insights for hypertension, heart failure, and rhythm management, and reducing alert fatigue.
Key Feature (Core Function) AI-based detection of Breast Arterial Calcifications (BAC); Processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams. Vendor-neutral data aggregation (all major OEMs: Medtronic, Boston Scientific, Abbott, Biotronik); AI-driven alert triage.
Key Feature (Integration/Reporting) Provides visualization of BAC location on a scorecard; Compatible with any DICOM-compliant viewer. Bi-directional EHR integration (Epic, Cerner, Athenahealth, etc.); Automated CPT code documentation and billing.
Specialties Cardiology, Obstetrics & Gynecology, Radiology Cardiology

Videos

Demos, reviews, and walkthroughs featuring cmAngio® and Rhythm360.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

cmAngiou00ae is FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment, primarily for Cardiology, Obstetrics & Gynecology, and Radiology specialties. Rhythm360 is an AI-powered platform that unifies cardiac monitoring data to provide actionable insights for hypertension, heart failure, and rhythm management, specifically targeting Cardiology.
cmAngiou00ae processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams and is compatible with any DICOM-compliant viewer. Rhythm360 offers vendor-neutral data aggregation from all major cardiac device OEMs and provides bi-directional EHR integration with systems like Epic, Cerner, and Athenahealth.
cmAngiou00ae analyzes mammogram images to detect and visualize Breast Arterial Calcifications (BAC), enabling identification and reporting without additional radiation. Rhythm360 aggregates and normalizes cardiac monitoring data from various devices, using AI to drive alert triage, manage heart failure with predictive algorithms, and optimize GDMT.
cmAngiou00ae uniquely offers AI-based BAC detection on mammograms with visualization on a scorecard and an adjustable operating point to meet clinical goals. Rhythm360 provides AI-driven alert triage for 80% faster response times, automated CPT code documentation and billing, and optional 24/7/365 oversight by certified cardiac technicians.
cmAngiou00ae is FDA-cleared, HIPAA-compliant, and offers a Business Associate Agreement (BAA) upon vendor contact. Rhythm360 is also HIPAA-compliant and provides a BAA, ensuring secure and compliant data handling.

Backers

Who funded each tool's parent company.

cmAngio®

AI Tool Finder
AI-powered search. Results may not be comprehensive.